OKYO Pharma Ltd
corporate_fare Company Profile
OKYO Pharma Ltd (NASDAQ:OKYO) is a publicly traded company in the Healthcare sector. Wiseek monitors OKYO SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- OKYO Pharma Expands Scientific Advisory Board with Key Ophthalmology Expert
- OKYO Pharma to Present Positive Phase 2 Urcosimod Data for Neuropathic Corneal Pain at Major Scientific Conferences
- OKYO Pharma Advances Lead Candidate Urcosimod with Positive Phase 2 Data and Pivotal Trial Plans
- Urcosimod Phase 2a Trial Shows Meaningful QoL Improvements in Neuropathic Corneal Pain
- OKYO Pharma Secures Additional $2.05M from Over-Allotment, Bringing Total Offering Proceeds to $22M
Financial Snapshot
Insider Transactions
OKYO files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.